Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Mar 3, 2025

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 28, 2025

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 24, 2025

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Feb 19, 2025

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 7, 2025

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Jan 6, 2025

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 11, 2024

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Dec 9, 2024

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 20, 2024